Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents

May 21, 2021, the coronavirus disease 2019 (Covid-19) pandemic has caused more than 165 million infections across all ages globally, as well as more than 3.4 million deaths.1 BNT162b2 (Pfizer–BioNTech) is a Covid-19 vaccine containing nucleoside-modified messenger RNA encoding the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein.2 In healthy adults, […]

Read More

Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants

The messenger RNA vaccine BNT162b2 (Pfizer–BioNTech) has 95% efficacy against coronavirus disease 2019 (Covid-19).1 Qatar launched a mass immunization campaign with this vaccine on December 21, 2020. As of March 31, 2021, a total of 385,853 persons had received at least one vaccine dose and 265,410 had completed the two doses. […]

Read More